Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity
Antonella Giannantoni, Savino M Di Stasi, Vincenza Nardicchi, Alessandro Zucchi, Lara Macchioni, Vittorio Bini, Gianfrancesco Goracci, Massimo Porena, Antonella Giannantoni, Savino M Di Stasi, Vincenza Nardicchi, Alessandro Zucchi, Lara Macchioni, Vittorio Bini, Gianfrancesco Goracci, Massimo Porena
Abstract
Purpose: We investigated the effects of BTX-A on visceral afferent nerve transmission by measuring bladder tissue NGF levels in patients with neurogenic detrusor overactivity before and after intravesical treatment with BTX-A. We also compared the bladder tissue NGF content with clinical and urodynamic data.
Materials and methods: A total of 23 patients underwent clinical evaluation and urodynamics with detection of the UDC threshold, maximum pressure and maximum cystometric capacity before, and at the 1 and 3-month followups. Endoscopic bladder wall biopsies were also obtained at the same time points. NGF levels were measured in tissue homogenate by enzyme-linked immunosorbent assay (Promega, Madison, Wisconsin).
Results: At 1 and 3 months mean catheterization and incontinent episodes were significantly decreased (p <0.05 and <0.001, respectively). On urodynamics we detected a significant increase in the UDC threshold and maximum cystometric capacity, and a significant decrease in UDC maximum pressure at the 1 and 3-month follow-ups compared to baseline (each p <0.001). At the same time points we detected a significant decrease in NGF bladder tissue content (each p <0.02).
Conclusions: BTX-A intravesical treatment induces a state of NGF deprivation in bladder tissue that persists at least up to 3 months. As caused by BTX-A, the decrease in acetylcholine release at the presynaptic level may induce a decrease in detrusor contractility and in NGF production by the detrusor muscle. Alternatively BTX-A can decrease the bladder level of neurotransmitters that normally modulate NGF production and release.
Source: PubMed
Prochains essais cliniques
-
NCT07643766Pas encore de recrutement
-
NCT07643779Pas encore de recrutementDouleur musculo-squelettique | Activité physique | Reflux gastro-oesophagien (RGO) | Symptôme
-
NCT07643792Pas encore de recrutementDouleur postopératoire | Personnes âgées | Chirurgie des fractures de la hanche | Bloc fascia iliaque | Bupivacaïne liposomale
-
NCT07643805Pas encore de recrutement
-
NCT07643818Pas encore de recrutementInsuffisance cardiaque avec fraction d'éjection préservée (ICFEP)
-
NCT07643844Pas encore de recrutementAcidémie propionique
-
NCT07643857Pas encore de recrutementComplications Postopératoires du Cancer Colorectal
-
NCT07643896RecrutementAneuploïdie | 22q11.2 Syndrome de délétion | Trisomie 18 | Trisomie 13 | Anomalies des chromosomes sexuels | Syndrome de Down (trisomie 21) | Pregnant Individuals
-
NCT07643909Pas encore de recrutementInsécurité alimentaire
-
NCT07643922Pas encore de recrutementHémorragie sous-arachnoïdienne, anévrismale | Vasospasme cérébral après une hémorragie sous-arachnoïdienne
-
NCT07643935Pas encore de recrutementCancer associé à la thérapie